Dark

LPTX
Leap Therapeutics Inc
stock NASDAQ

At Close

5/20/2022 3:59:54 PM EDT

1.17USD-3.306%(-0.04)538,930

0.9440Bid 1.18Ask 0.24Spread IEX

Pre-market

1969-12-31

0.00USD-100.000%(-1.21)0

After-hours

1969-12-31

0.00USD0.000%(0.00)0

Overview Option Chain HistoricalMore

open chart

Market Cap

103.333M

Headquarters

Cambridge, Massachusetts, USA

Industry

Biotechnology

Next Earnings

2022-08-12 (82d)

PDLI PIRS XLV

Jan 31, 2022

07:11AM EST Leica Biosystems , Leap Therapeutics Partner On Companion Diagnostic To Advance Care For Cancer Patients RTTNews

07:01AM EST Leica Biosystems and Leap Therapeutics Partner on Companion Diagnostic to PR Newswire

Jan 24, 2022

07:01AM EST Leap Therapeutics to Present at B. Riley Securities Oncology Investor Conference PR Newswire

Jan 19, 2022

07:40AM EST The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data Benzinga

Jan 18, 2022

05:02PM EST Leap Therapeutics To Present New Data From DisTinGuish Study Of DKN-01 Plus Tislelizumab At The ASCO GI Cancers Symposium Benzinga

More News

Stats

Avg. Vol. 10 Day

1,275,805

Avg. Vol. 30 Day

870,375

Employees

Market Cap

103,332,591

Shares Out.

88,318,454

Float

63,908,116

On/Off Exchange

46%/54%

6 Month Beta

2.12

1 Year Beta

1.69

2 Year Beta

1.23

3 Year Beta

1.06

52 Week Low

0.92

52 Week High

4.17

SMA50

1.45

SMA200

2.11

1 Week

-10.69%

1 Month

-20.41%

3 Month

-42.37%

6 Month

-45.07%

1 Year

-27.78%

2 Year

-45.07%

5 Year

-83.29%

Profile

Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.

LPTX Stock Summary

Leap Therapeutics Inc (NASDAQ:LPTX) stock price today is $1.17, and today's volume is 538,930. LPTX is down -3.306% today. The 30 day average volume is 870,375. LPTX market cap is 103.333M with 88,318,454 shares outstanding.

document.getElementById("bY62fc").onerror = function(){this.style.display='none';}; .dark-mode .Q5TCDN{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .Q5TCDN{ color: #333333; background-color: white; border: 2px solid #333333; }LPTXLeap Therapeutics Incstock NASDAQ

LPTX Stock Summary

LPTX
Leap Therapeutics Inc
stock NASDAQ